A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


February 16, 2012

Hep C, HIV Drug-Drug Interaction Studies Must Be a Priority, Activists Say

An international Hep C activist group is calling on government regulators and pharmaceutical companies developing therapies for hepatitis C virus (HCV) infection to conduct necessary interaction studies involving other medications commonly used by people living with HCV and HIV/HCV coinfection as early as possible. 

The Hepatitis C Community Advisory Board (HCAB), in a statement released Thursday, February 16, stressed their belief that it is possible to conduct such drug-drug interaction studies prior to U.S. Food and Drug Administration (FDA) approval without delaying development of novel therapies for HCV.

Because many emerging HCV drugs, frequently referred to as direct-acting antivirals (DAAs), are broken down (metabolized) by the same enzyme pathways responsible for processing many other medications used by people living with hepatitis C, including those who are also HIV positive, thoroughly exploring potential drug-drug interactions and ways to circumvent problems is important. Left unchecked, interactions can significantly decrease the effectiveness of some drugs while potentially increasing the risk of serious side effects from other drugs.

Early knowledge of interactions between DAAs and HIV-treating antiretrovirals is particularly crucial, given that roughly one third of people living with HIV are coinfected with HCV and are becoming increasingly dependent on the rapid availability of new DAAs.

“In recognition of the suboptimal efficacy and tolerability of peginterferon and ribavirin, rapid trajectory of liver disease progression and increasing mortality from HCV-related complications among HIV/HCV coinfected patients,” the HCAB statement reads, “regulators in the [United States] and the [European Union should] encourage sponsors to conduct trials in HIV/HCV coinfected patients prior to approval for [people living with HCV but not HIV].”

The HCAB statement stems from concerns related to the recent discovery of drug-drug interactions between Merck’s Victrelis (boceprevir) and Norvir (ritonavir)-boosted protease inhibitors used to treat HIV infection. “Although we commend [Merck] for opening one of the first coinfection trials with a DAA, we were outraged that Merck chose not to conduct [drug-drug interaction studies] with commonly used antiretroviral agents prior to launching the trial, and prior to gaining approval for boceprevir.”

“Vertex and Tibotec,” the statement authors add, “were able to bring [Incivek] telaprevir to market with a much fuller portfolio of [drug-drug interaction] data, although both drugs were developed within the same timeframe.”

HCAB is asking FDA, the European Medicines Agency (EMA) and pharmaceutical companies to work together to minimize potential harm to people living with HCV, including people coinfected with HIV and HCV, from uncharacterized drug-drug interactions.

“Furthermore,” the statement concludes, “we call upon sponsors to perform [drug-drug interaction] studies (as indicated by metabolic profile of their drug or drugs) with [Department of Health and Human Services, European AIDS Clinical Society and World Health Organization]-recommended antiretroviral agents for first-line, and treatment-experienced HIV/HCV coinfected people prior to approval, and strongly encourage studies of hormonal contraceptives, methadone, buprenorphine, lipid lowering agents, immunosuppressive drugs, herbal remedies, and commonly prescribed psychiatric medications.”

Search: hepatitis C, HCAB, HCV, HIV, drug-drug interactions, DDIs, metabolism, direct-acting antivirals, DAAs, protease inhibitors, Victrelis, boceprevir, Merck, FDA, EMA, DHHS, pharmaceutical companies

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.